Co-Authors
This is a "connection" page, showing publications co-authored by Elizabeth Blair and Daniel T. Ginat.
Connection Strength
2.710
-
Nasal cavity tumefactive fibroinflammatory lesion mimicking recurrent mucoepidermoid carcinoma. Ear Nose Throat J. 2017 Aug; 96(8):290-293.
Score: 0.627
-
Concurrent fungus ball and squamous cell carcinoma of the maxillary sinus. Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Apr; 133(2):153-4.
Score: 0.562
-
Laryngeal Swelling. JAMA Otolaryngol Head Neck Surg. 2015 Jul; 141(7):667-8.
Score: 0.543
-
A painful lesion of the mandible. Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Sep; 132(4):237-8.
Score: 0.538
-
Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib. Int J Surg Pathol. 2017 Oct; 25(7):613-618.
Score: 0.154
-
Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits. Cureus. 2022 Jul; 14(7):e27521.
Score: 0.055
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.053
-
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
Score: 0.052
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 10 01; 30(10):1673.
Score: 0.046
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.043
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
Score: 0.035